Results 101 to 110 of about 115,048 (305)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Therapeutics and Clinical Risk Management, 2017
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj  

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

B-cell Prolymphocytic Leukemia in a Young Male [PDF]

, 2011
B-cell prolymphocytic leukemia [B-PLL] is a neoplasm of B prolymphocytes affecting the peripheral blood, bone marrow and spleen. The principal disease characteristics are massive splenomegaly with absent or minimal peripheral lymphadenopathy and a ...
Fernandes, H, Jayaprakash, C, Pailoor, K, Swethadri, GK   +3 more
core  

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes

Advanced Science, EarlyView.
This study identifies that pregnancy imprints a durable, pregnancy‐specific form of trained immune memory in uterine macrophages, marked by the emergence of LILRB3+/PIR‐B+ cells that expand across gestations, acquire a tolerogenic and metabolically rewired phenotype, and actively protect against inflammatory pregnancy loss in mice.
Jing Wang, Ning Lu, Xin‐Xiu Lin, Xu‐Hui Fang, Yi‐Hui Li, Qing‐Peng Luo, Yu‐Ting Peng, Gil Mor, Ai‐Hua Liao   +8 more
wiley   +1 more source

Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase

Brazilian Journal of Medical and Biological Research, 2006
We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos, E.G. Rizzatti, A.B. Garcia, D.A.P. Gallo, R.P. Falcão   +4 more
doaj  

Biclonal Gammopathy in Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

Oman Medical Journal, 2015
Monoclonal gammopathies are frequently seen in B-cell malignancies. Monoclonal proteins are seen in a significant proportion of patients with chronic lymphocytic leukemia (CLL), which is a clonal disorder of mature B cells.
Nafila Al-Riyami, Khalil Al-Farsi, Khalfan Al-Amrani, Sameera Al-Harrasi, Mohammed Al-Huneini, Salam Al-Kindi   +5 more
doaj   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

Animal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam, Aashika Raagavi Jeanpierre, Salma Mohammed, Rajesh Srinivasan, Aman Kumar Mohanty   +4 more
wiley   +1 more source

Rheumatoid arthritis and B-cell chronic lymphocytic leukemia.

Clinical and experimental rheumatology, 2002
The association between lymphoproliferate malignancies, especially lymphoma, and rheumatoid arthritis (RA) has been confirmed by several studies. However; there are few reports of RA patients who developed B-cell chronic lymphocytic leukemia (B-CLL) and vice versa. We report a patient with B-CLL who developed RA and another with RA who presented with B-
Voulgari, P. V., Vartholomatos, G., Kaiafas, P., Bourantas, K. L., Drosos, A. A.   +4 more
openaire   +2 more sources